Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Ocular Therapeutix
OCUL
Ocular Therapeutix
Aging Global Trends And Novel Delivery Will Expand Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
06 Aug 25
Updated
21 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$22.00
46.0% undervalued
intrinsic discount
21 Aug
US$11.87
1Y
31.7%
7D
-3.6%
Loading
1Y
31.7%
7D
-3.6%
Author's Valuation
US$22.0
46.0% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$22.0
46.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-229m
246m
2014
2017
2020
2023
2025
2026
2028
Revenue US$245.9m
Earnings US$57.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
50.10%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$57.09m
Earnings '28
x
99.92x
PE Ratio '28
=
US$5.70b
Market Cap '28
US$5.70b
Market Cap '28
/
213.15m
No. shares '28
=
US$26.76
Share Price '28
US$26.76
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$21.98
Fair Value '25